JP6805130B2 - Ｃｄ１２３結合剤及びその使用 - Google Patents
Ｃｄ１２３結合剤及びその使用 Download PDFInfo
- Publication number
- JP6805130B2 JP6805130B2 JP2017512813A JP2017512813A JP6805130B2 JP 6805130 B2 JP6805130 B2 JP 6805130B2 JP 2017512813 A JP2017512813 A JP 2017512813A JP 2017512813 A JP2017512813 A JP 2017512813A JP 6805130 B2 JP6805130 B2 JP 6805130B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046682P | 2014-09-05 | 2014-09-05 | |
| US62/046,682 | 2014-09-05 | ||
| PCT/US2015/048316 WO2016036937A1 (en) | 2014-09-05 | 2015-09-03 | Cd123 binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Division JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529838A JP2017529838A (ja) | 2017-10-12 |
| JP2017529838A5 JP2017529838A5 (enExample) | 2018-10-11 |
| JP6805130B2 true JP6805130B2 (ja) | 2020-12-23 |
Family
ID=54150667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512813A Active JP6805130B2 (ja) | 2014-09-05 | 2015-09-03 | Ｃｄ１２３結合剤及びその使用 |
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Country Status (39)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2560993T3 (pl) * | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| MY191964A (en) | 2015-01-23 | 2022-07-21 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| EP3842459A1 (en) * | 2015-06-29 | 2021-06-30 | ImmunoGen, Inc. | Anti-cd123 antibodies and conjugates and derivatives thereof |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| CA3024723A1 (en) | 2016-05-20 | 2017-11-23 | Robert B. Dubridge | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| PT3461261T (pt) * | 2016-05-20 | 2025-07-31 | Harpoon Therapeutics Inc | Proteínas de ligação ao cd3 de fragmento variável de cadeia única |
| IL262996B2 (en) * | 2016-06-06 | 2024-03-01 | Hoffmann La Roche | Fusion proteins for ophthalmology with increased eye retention |
| US20200255524A1 (en) | 2016-06-07 | 2020-08-13 | Macrogenics, Inc. | Combination therapy |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
| US11242400B2 (en) * | 2016-09-21 | 2022-02-08 | Aptevo Research And Development Llc | CD123 binding proteins and related compositions and methods |
| EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
| KR20190087539A (ko) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| JP7231549B2 (ja) * | 2017-02-06 | 2023-03-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CN108570109B (zh) * | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
| CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
| BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| US20210061911A1 (en) * | 2017-09-07 | 2021-03-04 | Macrogenics, Inc. | Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| JP7084990B2 (ja) | 2017-10-13 | 2022-06-15 | ハープーン セラピューティクス，インク． | 三重特異性タンパク質と使用方法 |
| PE20201255A1 (es) * | 2017-10-27 | 2020-11-16 | Pfizer | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos |
| WO2019118266A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| CA3093330A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| CA3100157A1 (en) | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
| PE20211916A1 (es) | 2018-05-24 | 2021-09-28 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| MA52772A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| US20220275080A1 (en) * | 2018-10-17 | 2022-09-01 | Good T Cells, Inc. | Binding molecule specific to lrig-1 protein, and use thereof |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| WO2020183245A2 (en) * | 2019-03-11 | 2020-09-17 | Janssen Pharmaceutica Nv | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
| CN113747944A (zh) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | 用抗psma/cd3抗体治疗前列腺癌的方法 |
| PE20220763A1 (es) * | 2019-05-08 | 2022-05-16 | Janssen Biotech Inc | Materiales y metodos para modular la inmunidad mediada por celulas t |
| US12516128B2 (en) | 2019-05-14 | 2026-01-06 | Harpoon Therapeutics, Inc. | EpCAM binding proteins and methods of use |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| CN113912696B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白与其应用 |
| GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| CA3170330A1 (en) | 2020-02-21 | 2021-08-26 | Macrogenics, Inc. | Cd137 binding molecules and uses thereof |
| US20240293453A1 (en) | 2020-03-13 | 2024-09-05 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
| US20210363252A1 (en) * | 2020-05-19 | 2021-11-25 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor |
| GB2612713B (en) | 2020-05-19 | 2025-12-17 | Univ California | Conjugate polypeptides and vaccines for inducing immune responses |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| EP4232071A4 (en) * | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| JP7623497B2 (ja) | 2020-12-31 | 2025-01-28 | サノフイ | ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ |
| SI4284512T1 (sl) | 2021-01-28 | 2025-06-30 | Regeneron Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje sindroma sproščanja citokinov |
| BR112023024209A2 (pt) * | 2021-05-18 | 2024-01-30 | Janssen Biotech Inc | Composições que compreendem um agente terapêutico de redirecionamento de células t e um agente terapêutico anti-cd44 |
| KR20240024829A (ko) | 2021-05-19 | 2024-02-26 | 애셔 바이오테라퓨틱스, 인크. | Il-21 폴리펩타이드 및 표적화된 작제물 |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| IL322545A (en) | 2023-02-17 | 2025-10-01 | Regeneron Pharma | Induced NK cells responding to bispecific CD3/TAA antibodies |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1997024373A1 (en) | 1995-12-29 | 1997-07-10 | Medvet Science Pty. Limited | Monoclonal antibody antagonists to haemopoietic growth factors |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| DK1015576T3 (da) | 1997-09-16 | 2005-08-29 | Egea Biosciences Llc | Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| AU2006317242A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| PT2426148E (pt) * | 2009-04-27 | 2015-10-26 | Kyowa Hakko Kirin Co Ltd | Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue |
| AU2010298036B2 (en) * | 2009-09-25 | 2015-05-21 | Xoma Technology Ltd. | Screening methods |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| AU2012332021B8 (en) | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
-
2015
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/en not_active Ceased
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/en active Active
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/me unknown
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en not_active Ceased
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active Active
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/en active Active
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 SM SM20200253T patent/SMT202000253T1/it unknown
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/en not_active Withdrawn
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 MX MX2017002891A patent/MX384424B/es unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
-
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
-
2020
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6805130B2 (ja) | Ｃｄ１２３結合剤及びその使用 | |
| JP7469432B2 (ja) | 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 | |
| US20190270826A1 (en) | Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof | |
| JP2024507180A (ja) | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 | |
| HK40039447A (en) | Cd123 binding agents and uses thereof | |
| BR112017004322B1 (pt) | ANTICORPO BIESPECÍFICO CD123 (IL3-RA) x CD3 ISOLADO, OU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO, USOS DOS MESMOS, COMPOSIÇÃO FARMACÊUTICA, E KIT | |
| HK1240948B (zh) | Cd123结合剂及其用途 | |
| HK1240948A1 (en) | Cd123 binding agents and uses thereof | |
| BR122024008695A2 (pt) | Anticorpos anti-gprc5d, anticorpo isolado biespecífico para gprc5d x cd3, usos dos mesmos, composição farmacêutica, métodos para gerar os ditos anticorpos, célula e polinucleotídeos sintéticos isolados, e kit | |
| BR122024008681A2 (pt) | Anticorpos anti-gprc5d, anticorpo isolado biespecífico para gprc5d x cd3, usos dos mesmos, composição farmacêutica, métodos para gerar os ditos anticorpos, célula e polinucleotídeos sintéticos isolados, e kit | |
| BR122024008676A2 (pt) | Anticorpos anti-gprc5d, anticorpo isolado biespecífico para gprc5d x cd3, usos dos mesmos, composição farmacêutica, métodos para gerar os ditos anticorpos, célula e polinucleotídeos sintéticos isolados, e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180831 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191001 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6805130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |